Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
153/433
Matches for
“Prognostic factors”
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
…This paper aims to assess the 5-year prognostic values of these…
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
…The aim of the study was to compare the diagnostic and prognostic…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
…We compared the 4-year prognostic value of combining FT-AT and…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
…The prognostic value (AUROC / Cox risk ratio) of FibroTest in patients with…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
…FibroTest has prognostic value for predicting overall survival in patients with type…
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
…stiffness and FibroTest values increased. Prognostic values of stiffness (P<.0001) and…
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
…We aimed to describe the prognostic performance of four widely used NITs…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
…To evaluate the 5-year prognostic value of liver stiffness, non-invasive…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
…The primary prognostic endpoint was the age-and sex-adjusted risk of…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
…The secondary aim was to provide an overview of the prognostic value…
-
Assessment of liver fibrosis: noninvasive means.
…be due to biopsy; the prognostic value of FibroTest is at least…
-
Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.
…We investigated the prognostic role of the combined use of LS and…
-
Liver fibrosis markers in alcoholic liver disease.
Alcohol is one of the main factors of liver damage. The evaluation…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…
-
Noninvasive diagnosis in alcohol-related liver disease. Review
### Background Alcohol-related liver disease (ALD) represents a major cause of death…
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
### Background Since 1920, a decrease in serum cholesterol has been identified as…
-
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.
…Sensitivity analysis assessed the impact of several factors, including authors' independence, length…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.
…The staging of liver fibrosis still represents the most important prognostic problem…
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
…Use of general prognostic indices may help identify HCV patients at high…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
…progression and regression, with similar prognostic values. The aim was to estimate…
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
### Background & Aims The first aim was to extend the validation of FibroTest…
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
…aimed to evaluate the possible prognostic value of ActiTest and FibroTest proteins…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
Biomarkers of liver fibrosis.
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Liver biopsy: the best standard...when everything else fails.
-
Noninvasive evaluation of NAFLD.
A common clinical concern in patients with NAFLD is whether they have…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
### Background Liver biopsy and virological end points are standard references for assessing…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
### Background Blood tests of liver injury are less well validated in non…
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
### Background/Aims The aim was to identify a panel of biomarkers (AshTest…
-
Non-invasive diagnosis and follow-up of portal hypertension.
Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis…
-
FibroMAX: towards a new universal biomarker of liver disease?
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
…The following factors were associated with LFP to F4 (all p<0…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?
…1) the presence of cirrhosis has prognostic relevance as it entails a…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.
### Objective Studies have shown that patients with failing Fontan circulation may develop…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
…apolipoproteinA1, haptoglobin) with known risk factors (gender, age, gammaglutamyltranspeptidase), and a marker…
-
The non-invasive assessment of hepatic fibrosis.
…one of the most relevant prognostic factors. The liver biopsy with the…
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
### Background Assessment of fibrosis progression in chronic liver disease relies upon non…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
…known hepatocellular carcinoma (HCC) risk factors (sex, age, and gamma-glutamyl transferase…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
…Despite more metabolic risk factors in one cohort, results were similar according…
-
Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.
### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…
-
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.
…of cirrhosis and may have prognostic value in this setting. Guidelines are…
-
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
### Background & Aims In patients with compensated alcohol-related cirrhosis, reliable prognostic biomarkers…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
…F4 using biopsy, and as prognostic markers of liver related mortality in…
-
Non-invasive markers for hepatic fibrosis.
…pathogens, and many other etiologic factors. Current non-invasive methods range from…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
…studies reporting the diagnostic and prognostic accuracy of the ELF test, FibroTest…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
…apolipoproteinA1, haptoglobin) with known risk factors (gender, age, gammaglutamyltranspeptidase), and a marker…
-
Hepatitis B: are non-invasive markers of liver fibrosis reliable?
Liver biopsy, which was traditionally considered to be the gold standard for…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
…Factors independently associated (all P < 0.003) with confirmed fibrosis were age…
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.
The assessment of the fibrotic evolution of chronic hepatitis has always been…
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.
…haptoglobin), hepatocellular carcinoma (HCC) risk factors (gender, age, gamma glutamyl transpeptidase), a…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
### Background & Objectives One of the multiple factors contributing to virological response in…
-
Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.
### Background And Aims We aimed to determine the best algorithms for the…
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
…survivals before adjusting for confounding factors. With the exception of cholelithiasis in…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
### Objective There is a controversy about the performance of blood tests for…
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
…time, and provide long-term prognostic information. Although clinically useful, current biomarker…
-
Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Applicability and variability of liver stiffness measurements according to probe position.
### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.
Chronic hepatitis B virus (HBV) infection is a major cause of liver…
-
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
### Aim To assess the performance of several non-invasive markers and of…
-
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
…the variability of metabolic risk factors between the different control groups. This…
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.
### Background The efficiency of transient elastography for the assessment of liver fibrosis…
-
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
### Background Liver disease is the third leading cause of mortality in patients…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
…By multivariate analysis, independent factors for liver steatosis were, as expected, triglyceride…
-
Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.
Changes in the liver and bile ducts observed in patients diagnosed with…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
### Background Few data are available on chronic hepatitis C (CHC) in elderly…
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
### Background The best technique to estimate portal hypertension (PHT) is to measure…
-
Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.
### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…
-
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
### Background And Aims The PGAA index was one of the first composite…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.
### Background Chronic HCV is one of the major causes of morbidity and…
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
The aim of this study was to evaluate the diagnostic usefulness of…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
### Objectives Extent of liver fibrosis is one of the most important factors…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
…Baseline prognostic factors were combined using logistic regression analysis in a training…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
…Investigators from studies targeting patients with risk factors of liver disease, such…
-
Noninvasive assessment of portal hypertension in patients with cirrhosis.
Severe portal hypertension is responsible for complications and death. Although measurement of…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.
### Background Previous research has shown variation in the effects of patient factors…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
…for baseline LLACS and risk factors for lower extremity artery disease (β…
-
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
Hepatitis C virus (HCV) infection is a major cause of chronic liver…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
### Background One of the unmet needs in patients with type 2 diabetes…
-
The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.
The aim of this study was to investigate whether the non-invasive…
-
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
…03] were considered as risk factors of discordance in multivariate analysis. ### Conclusion…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…
-
Glycogenic hepatopathy.
### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…
-
Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.
Haemophilia is an entity, wherein the HCV infection rate is greater than…
-
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.
Fontan-associated liver disease (FALD) is a serious complication related to the…
-
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…
-
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
### Background And Aims Primary prevention of variceal bleeding with beta-blockers improves…
-
Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.
### Aim The objective of this study was to evaluate liver fibrosis using…
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…
-
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
…fibrosis index based on four factors (FIB-4), Age-platelet(AP) index…
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
### Background In recent years noninvasive methods have been evaluated for the assessment…
-
Changes of non-invasive markers and FibroScan values during HCV treatment.
The recent advent of non-invasive methods for assessment of fibrosis allows…
-
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.
FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
…The aim was to identify factors associated with LSM accuracy using FT…
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Reproducibility of blood tests of liver fibrosis in clinical practice.
### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
### Background/Aims The aim of this study was to compare the performance…
-
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
### Objectives Precise evaluation of the level of liver fibrosis is recommended in…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
…drugs were the main risk factors for hepatotoxicity. ### Conclusions : More than half…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
…In CHB, IR was related to host and not viral factors. CHB…
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
…We assessed the effect of nine factors on fibrosis progression: age at…
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
### Background And Aims Real-time shear wave elastography (2D-SWE) is a…
-
[Prognosis assessment of alcoholic liver disease: how and why?].
Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
…of the traditional cardiovascular risk factors included in the SCORE2-Diabetes model…
-
Management of the patient with SVR. Review
In the current era of therapy with direct-acting antiviral (DAAs) drugs…
-
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
### Background This prospective, monocentric study was designed to assess the efficacy of…
-
Non-invasive diagnosis of hepatitis B virus-related cirrhosis.
Chronic hepatitis B (CHB) infection is a major public health problem associated…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered the gold standard for assessing histologic lesions…
-
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
…In MASLD, trajectories of proxies and incidence against confounding factors used hazard…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages].
Liver cirrhosis in Mexico is one of the most important causes of…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.
### Background Liver fibrosis is a sign of advanced liver disease and is…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Ministère des Affaires Sociales et de la Santé Key publication
Showing the full result list. The page is server-rendered and not paginated.